比伐芦定联合高剂量输注与肝素单药治疗在直接PCI的STEMI患者中的随机试验
BRIGHT-4是一项由研究者发起、开放标签、随机对照试验,在中国63个城市87个临床中心纳入6016例发病48小时内、经桡动脉入路行直接PCI、未接受过溶栓/抗凝/糖蛋白IIb/IIIa抑制剂的STEMI患者,1:1随机接受比伐芦定联合术后2-4小时高剂量输注或普通肝素单药治疗。主要终点30天全因死亡或BARC 3-5型出血:肝素组132例(4.39%)vs 比伐芦定组92例(3.06%),差异1.33%(95%CI 0.38-2.29%),HR 0.69(95%CI 0.53-0.91),p=0.0070。30天全因死亡肝素组118例(3.92%)vs 比伐芦定组89例(2.96%)(HR 0.75,95%CI 0.57-0.99,p=0.0420),BARC 3-5型出血肝素组24例(0.80%)vs 比伐芦定组5例(0.17%)(HR 0.21,95%CI 0.08-0.54,p=0.0014),支架内血栓比伐芦定组11例(0.37%)vs 肝素组33例(1.10%)(p=0.0015)。再梗死、卒中或缺血驱动的靶血管血运重建30天发生率两组无显著差异。
要点
- STEMI直接PCI(93.1%经桡动脉)患者中,比伐芦定联合术后2-4小时高剂量输注较肝素单药降低30天全因死亡或BARC 3-5型出血复合终点(3.06% vs 4.39%,HR 0.69,95%CI 0.53-0.91,p=0.0070)。
- 30天全因死亡:比伐芦定组2.96% vs 肝素组3.92%(HR 0.75,95%CI 0.57-0.99,p=0.0420)。
- 30天BARC 3-5型出血:比伐芦定组0.17% vs 肝素组0.80%(HR 0.21,95%CI 0.08-0.54,p=0.0014)。
- 30天支架内血栓:比伐芦定组0.37% vs 肝素组1.10%(p=0.0015);再梗死、卒中或缺血驱动靶血管血运重建两组无显著差异。
- 两组糖蛋白IIb/IIIa抑制剂均仅用于术中血栓并发症。
适用人群与场景
- 发病48小时内行直接PCI的STEMI患者,经桡动脉入路,且未接受过溶栓治疗、抗凝药或糖蛋白IIb/IIIa抑制剂。
- 中国63个城市87个临床中心,随机分组1:1,开放标签。
处置流程与药物剂量
- 比伐芦定组:比伐芦定联合术后高剂量输注2-4小时。
- 对照组:普通肝素单药治疗。
- 两组糖蛋白IIb/IIIa抑制剂均仅用于术中血栓并发症。
研究设计与关键结果
- BRIGHT-4为研究者发起、开放标签、随机对照试验,87个中心,纳入6016例STEMI直接PCI患者,比伐芦定联合术后高剂量输注组3009例 vs 肝素单药组3007例。
- 主要终点30天全因死亡或BARC 3-5型出血:肝素组132例(4.39%)vs 比伐芦定组92例(3.06%),差异1.33%(95%CI 0.38-2.29%),HR 0.69(95%CI 0.53-0.91),p=0.0070。
- 30天全因死亡:肝素组118例(3.92%)vs 比伐芦定组89例(2.96%),HR 0.75(95%CI 0.57-0.99),p=0.0420。
- 30天BARC 3-5型出血:肝素组24例(0.80%)vs 比伐芦定组5例(0.17%),HR 0.21(95%CI 0.08-0.54),p=0.0014。
- 30天支架内血栓:比伐芦定组11例(0.37%)vs 肝素组33例(1.10%),p=0.0015。
- 30天再梗死、卒中或缺血驱动的靶血管血运重建两组无显著差异。
- 桡动脉入路5593例(93.1%)/6008例。
证据类型、等级与局限
- 证据类型:研究者发起的开放标签随机对照试验(BRIGHT-4),注册号NCT03822975,试验正在进行中。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在以桡动脉入路为主的STEMI直接PCI患者中,比伐芦定联合术后2-4小时高剂量输注较肝素单药显著降低30天全因死亡或BARC 3-5型大出血复合终点。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Previous randomised trials of bivalirudin versus heparin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) have reported conflicting results, in part because of treatment with different pharmacological regimens. We designed a large-scale trial examining bivalirudin with a post-PCI high-dose infusion compared with heparin alone, the regimens that previous studies have shown to have the best balance of safety and efficacy.
METHODS: BRIGHT-4 was an investigator-initiated, open-label, randomised controlled trial conducted at 87 clinical centres in 63 cities in China. Patients with STEMI undergoing primary PCI with radial artery access within 48 h of symptom onset who had not received previous fibrinolytic therapy, anticoagulants, or glycoprotein IIb/IIIa inhibitors were randomly assigned (1:1) to receive bivalirudin with a post-PCI high-dose infusion for 2-4 h or unfractionated heparin monotherapy. There was no masking. Glycoprotein IIb/IIIa inhibitor use was reserved for procedural thrombotic complications in both groups. The primary endpoint was a composite of all-cause mortality or Bleeding Academic Research Consortium (BARC) types 3-5 bleeding at 30 days. This trial is registered with ClinicalTrials.gov (NCT03822975), and is ongoing.
FINDINGS: Between Feb 14, 2019, and April 7, 2022, a total of 6016 patients with STEMI undergoing primary PCI were randomly assigned to receive either bivalirudin plus a high-dose infusion after PCI (n=3009) or unfractionated heparin monotherapy (n=3007). Radial artery access was used in 5593 (93·1%) of 6008 patients. Compared with heparin monotherapy, bivalirudin reduced the 30-day rate of the primary endpoint (132 events [4·39%] in the heparin group vs 92 events [3·06%] in the bivalirudin group; difference, 1·33%, 95% CI 0·38-2·29%; hazard ratio [HR] 0·69, 95% CI 0·53-0·91; p=0·0070). All-cause mortality within 30 days occurred in 118 (3·92%) heparin-assigned patients and in 89 (2·96%) bivalirudin-assigned patients (HR 0·75; 95% CI 0·57-0·99; p=0·0420), and BARC types 3-5 bleeding occurred in 24 (0·80%) heparin-assigned patients and five (0·17%) bivalirudin-assigned patients (HR 0·21; 95% CI 0·08-0·54; p=0·0014). There were no significant differences in the 30-day rates of reinfarction, stroke, or ischaemia-driven target vessel revascularisation between the groups. Within 30 days, stent thrombosis occurred in 11 (0·37%) of bivalirudin-assigned patients and 33 (1·10%) of heparin-assigned patients (p=0·0015).
INTERPRETATION: In patients with STEMI undergoing primary PCI predominantly with radial artery access, anticoagulation with bivalirudin plus a post-PCI high-dose infusion for 2-4 h significantly reduced the 30-day composite rate of all-cause mortality or BARC types 3-5 major bleeding compared with heparin monotherapy.
FUNDING: Chinese Society of Cardiology Foundation (CSCF2019A01), and a research grant from Jiangsu Hengrui Pharmaceuticals.
参考来源
- Li Y, Liang Z, Qin L, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. Lancet. 2022. PMID: 36351459. doi:10.1016/S0140-6736(22)01999-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。